Följ oss

Nyheter

Value Renaissance

Publicerad

den

The rebound of value stocks suggests the style shift is pricing a moderate recovery in earnings. Value Renaissance

ETF Securities Equity Research – Value Renaissance

Highlights

  • The rebound of value stocks suggests the style shift is pricing a moderate recovery in earnings.
  • Sector selection and sentiment has driven the shift in style bias in favour of growth stocks over the past decade.
  • Widest historical Price to Book (P/B) spread confirms Value is trading at a steep discount to Growth.
  • Global macro factors support the case for a return to value investing but there are risks on the horizon.

Value investors are anticipating a change in the cycle

The key to long term investment gains is ingrained in retaining a disciplined strategy. The main but contrasting investment approaches are value and growth investing. Value investing involves buying stocks at a discount to market price and such discounts can be identified by using multiples (of earnings, cash flow and book value). Growth investing involves buying companies undergoing above average growth in earnings and are identified by high profitability margins and return on equity. Owing to its inherently higher operating leverage, historically Value outperforms Growth ahead of a turn in the profit cycle (with a lead of about 2 years). As the global macro environment improves, we are seeing emerging signs of value stocks being bid up by investors as they try to capitalise on the recovery in global economic activity. ´

(Click to enlarge)

There has been a bias towards growth investing over the past decade, leading some to question if value investing is dead.

Sector selection held value back

Value oriented indices currently have a higher weighting to finance and energy sectors than growth oriented indices. Technology and consumer discretionary stocks account for the highest weights in growth oriented indices.

(Click to enlarge)

Falling oil prices, and difficulties in the banking sector since the global financial crisis, led to a period of earnings deceleration among the value oriented finance and energy sectors. On the other hand, technology and consumer discretionary stocks posted stronger earnings tilting investor preferences towards growth stocks since 2008. Consequently, sector selection was largely responsible for the recent style bias in favour of growth stocks. We don’t think that there has been a breakdown in the fundamentals of value investing but the style has been unpopular due to sector-specific reasons. During the dot com mania of the late 90’s, value investors suffered greatly as they missed out on the rally of technology stocks whose weighting was nearly 50% of the MSCI World growth index. However, as the bubble deflated, the weight of the technology sector reduced to around 20% and Value came back in favour.

Sentiment has had a part to play in the style shift since 2008, as investors have been exposed to the dominance of central bank policy, negative interest rates, lower commodity prices and weaker expectations of economic growth. In this scenario investors have resorted to investing in growth stocks and  capturing yield via bond proxies within a mix of both value (utilities, telecom, real estate) and growth (consumer staples, and healthcare) equity sectors.

Value at a bargain but not for long

Value stocks are trading at their steepest discount in history to Growth. On analysing the P/B ratios of stocks across US, Europe and Japan, we found that the gap between the cheapest part of the global equity market and the most expensive is currently at its widest level since 1986. This suggests value stocks are trading at an unprecedented discount relative to its expensive peers. The last occasions we witnessed spreads come anywhere close were during the technology bubble of the late 90’s and prior to the global financial crisis in 2008.

(Click to enlarge)

Value will benefit from higher rates

Strong US economic data, coupled with Trump’s pro-growth mandate have raised expectations for higher global growth rates accompanied by increasing inflation. The imminent US rate hike in December has become a near certainty and a higher inflation outlook has fuelled the prospects of additional rate hikes by the Fed next year. We expect value to benefit as the rate tightening cycle continues in the US. History shows that, in the 6 to 12-month period following the start of the US rate tightening cycle, Value has outperformed Growth.

(Click to enlarge)

We are currently seeing early signs of Value outpacing Growth as the rhetoric for additional rate hikes in 2017 sets in, similar to 1986, 1999 and 2004.

Macro factors support Value’s reversion to the mean

The trajectory of bonds yields in the US and Europe have a strong relationship with the relative valuation spread of Value versus Growth, based on Price to Earnings (P/E). The recent rise in bond yields sparked by the risk-on environment, subsequent to Trump’s presidential victory, has been closely tracked by the rising performance of value versus growth stocks. We expect this trend to continue to benefit value stocks as they displace the defensive bond-proxy trades towards more cyclically oriented value stocks. In addition, we expect the steepening of the yield curve to benefit financial stocks that are known to represent a large part of the value style.

(Click to enlarge)

Fundamentals intact but risks linger

Despite the prolonged underperformance of value investing since the global financial crisis, we believe the fundamentals remain intact. The historical rotation of investing style bias is reflective of the performance of the main underlying sectors within each style. While Growth and Value are not trading at a significant discount to each other, Value is clearly trading at an unprecedented discount to its historical spread. Investors are picking up on the trend, evident from the sharp reversal in the performance of Value in 2016. Over time we have observed a shift towards value investing to serve as a timely indicator of an initial acceleration in global earnings. We feel the current shift in style is a precursor of a continued recovery.

While improving global macro data is a catalyst for Value, we acknowledge the risk to the scenario remains that the market could be overpricing the rate rising cycle and the recovery in earnings momentum. We also remain extremely cautious of the euphoria surrounding Trump’s victory and remain uncertain of his ability to implement all his pro-growth policies that are subject to raising the US debt ceiling. Also, the reversal of the bond proxy trades skewed towards value sectors such as utilities, telecom and real estate could negatively impact Value’s upside performance. Despite the looming risks, we maintain our stance that growth stocks have run ahead of its course and Value offers an attractive entry point with the potential for a meaningful recovery to the upside.

Important Information

General

This communication has been issued and approved for the purpose of section 21 of the Financial Services and Markets Act 2000 by ETF Securities (UK) Limited (“ETFS UK”) which is authorised and regulated by the United Kingdom Financial Conduct Authority (the “FCA”).

Fortsätt läsa
Annons
Klicka för att kommentera

Skriv en kommentar

Din e-postadress kommer inte publiceras. Obligatoriska fält är märkta *

Nyheter

Fastställd utdelning i MONTDIV april 2025

Publicerad

den

Idag fastställdes utdelningen i MONTDIV april 2025. Montrose Global Monthly Dividend MSCI World UCITS ETF (MONTDIV ETF) fastställdes till 0,39465 kronor per andel. Utdelningen i MONTDIV april 2025 beräknas betalas ut den 12 maj 2025.

Idag fastställdes utdelningen i MONTDIV april 2025. Montrose Global Monthly Dividend MSCI World UCITS ETF (MONTDIV ETF) fastställdes till 0,39465 kronor per andel. Utdelningen i MONTDIV april 2025 beräknas betalas ut den 12 maj 2025.

Handla MONTDIV ETF

Montrose Global Monthly Dividend MSCI World UCITS ETF (MONTDIV ETF) är en europeisk börshandlad fond. Denna fond handlas på Nasdaq Stockholm.

Det betyder att det går att handla andelar i denna ETF genom de flesta svenska banker och Internetmäklare, till exempel  NordnetSAVRDEGIRO och Avanza.

Fortsätt läsa

Nyheter

WELG ETF en satsning på healthcareföretag världen över

Publicerad

den

Amundi S&P Global Health Care ESG UCITS ETF DR EUR (D) (WELG ETF) med ISIN IE000JKS50V3, strävar efter att spåra S&P Developed Ex-Korea LargeMidCap Sustainability Enhanced Health Care-index. Det S&P-utvecklade ex-Korea LargeMidCap Sustainability Enhanced Health Care-indexet spårar stora och medelstora företag från hälso- och sjukvårdssektorn. Aktierna som ingår filtreras enligt ESG-kriterier (miljö, social och bolagsstyrning).

Amundi S&P Global Health Care ESG UCITS ETF DR EUR (D) (WELG ETF) med ISIN IE000JKS50V3, strävar efter att spåra S&P Developed Ex-Korea LargeMidCap Sustainability Enhanced Health Care-index. Det S&P-utvecklade ex-Korea LargeMidCap Sustainability Enhanced Health Care-indexet spårar stora och medelstora företag från hälso- och sjukvårdssektorn. Aktierna som ingår filtreras enligt ESG-kriterier (miljö, social och bolagsstyrning).

Den börshandlade fondens TER (total cost ratio) uppgår till 0,18 % p.a. Amundi S&P Global Health Care ESG UCITS ETF DR EUR (D) är den billigaste ETF som följer S&P Developed Ex-Korea LargeMidCap Sustainability Enhanced Health Care-index. ETFen replikerar det underliggande indexets prestanda genom fullständig replikering (köper alla indexbeståndsdelar). Utdelningarna i ETFen delas ut till investerarna (Årligen).

Amundi S&P Global Health Care ESG UCITS ETF DR EUR (D) är en mycket liten ETF med 17 miljoner euro förvaltade tillgångar. ETFen lanserades den 20 september 2022 och har sin hemvist i Irland.

Investeringsmål

AMUNDI S&P GLOBAL HEALTH CARE ESG UCITS ETF DR – EUR (D) försöker replikera, så nära som möjligt, resultatet av S&P Developed Ex-Korea LargeMidCap Sustainability Enhanced Health Care Index (Netto Total Return Index). Denna ETF har exponering mot stora och medelstora företag i utvecklade länder. Den innehåller uteslutningskriterier för tobak, kontroversiella vapen, civila och militära handeldvapen, termiskt kol, olja och gas (inkl. Arctic Oil & Gas), oljesand, skiffergas. Den är också utformad för att välja ut och omvikta företag för att tillsammans förbättra hållbarhet och ESG-profiler, uppfylla miljömål och minska koldioxidavtrycket.

Handla WELG ETF

Amundi S&P Global Health Care ESG UCITS ETF DR EUR (D) (WELG ETF) är en europeisk börshandlad fond. Denna fond handlas på flera olika börser, till exempel Deutsche Boerse Xetra.

Det betyder att det går att handla andelar i denna ETF genom de flesta svenska banker och Internetmäklare, till exempel DEGIRONordnet, Aktieinvest och Avanza.

Börsnoteringar

BörsValutaKortnamn
gettexEURWELG
XETRAUSDWELZ
XETRAEURWELG

Största innehav

Denna fond använder fysisk replikering för att spåra indexets prestanda.

NamnValutaViktSektor
ELI LILLY & COUSD10.29 %Health Care
UNITEDHEALTH GROUP INCUSD7.99 %Health Care
NOVO NORDISK A/S-BDKK6.32 %Health Care
ABBVIE INCUSD6.12 %Health Care
ASTRAZENECA GBPGBP5.26 %Health Care
ROCHE HOLDING AG – GENUSSSCHF4.18 %Health Care
MERCK & CO. INC.USD3.93 %Health Care
NOVARTIS AG-REGCHF3.70 %Health Care
ABBOTT LABORATORIESUSD3.43 %Health Care
SANOFIEUR2.58 %Health Care

Innehav kan komma att förändras

Fortsätt läsa

Nyheter

Amundi noterar ETF för globala företagsobligationer

Publicerad

den

Amundi Global Corporate Bond UCITS ETF investerar globalt i företagsobligationer med fast ränta, denominerade i lokal valuta och har en investment grade-rating. De måste ha en återstående löptid på minst ett år.

Amundi Global Corporate Bond UCITS ETF investerar globalt i företagsobligationer med fast ränta, denominerade i lokal valuta och har en investment grade-rating. De måste ha en återstående löptid på minst ett år.

Andelsklassen är valutasäkrad mot amerikanska dollar och delar ut avkastningen.

NamnISIN
Kortnamn
KostnadUtdelnings-
policy
Amundi Global Corporate Bond UCITS ETF USD Hedged DistLU2996613266
USBG (USD)
0,17%Utdelande

Produktutbudet inom Deutsche Börses ETF- och ETP-segment omfattar för närvarande totalt 2 405 ETFer, 198 ETCer och 256 ETNer. Med detta urval och en genomsnittlig månatlig handelsvolym på mer än 21 miljarder euro är Xetra den ledande handelsplatsen för ETFer och ETPer i Europa.

Fortsätt läsa

Populära